Ryuta Asada

780 total citations
20 papers, 503 citations indexed

About

Ryuta Asada is a scholar working on Pathology and Forensic Medicine, Epidemiology and Genetics. According to data from OpenAlex, Ryuta Asada has authored 20 papers receiving a total of 503 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Pathology and Forensic Medicine, 5 papers in Epidemiology and 4 papers in Genetics. Recurrent topics in Ryuta Asada's work include Lymphoma Diagnosis and Treatment (4 papers), Health Systems, Economic Evaluations, Quality of Life (3 papers) and Inflammatory Myopathies and Dermatomyositis (3 papers). Ryuta Asada is often cited by papers focused on Lymphoma Diagnosis and Treatment (4 papers), Health Systems, Economic Evaluations, Quality of Life (3 papers) and Inflammatory Myopathies and Dermatomyositis (3 papers). Ryuta Asada collaborates with scholars based in Japan and United States. Ryuta Asada's co-authors include Takashi Kimura, Yoshihiro Fujimura, Takashi Tsuji, S. Harada, Yoshiaki Sonoda, S Yokota, Jean Wang, Susumu Ikehara, Toshiyuki Fukao and Michio Ozeki and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Ryuta Asada

19 papers receiving 500 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ryuta Asada Japan	9	128	127	122	110	86	20	503
Shasha Zhao China	14	130 1.0×	49 0.4×	125 1.0×	107 1.0×	180 2.1×	46	611
Zafer Başlar Türkiye	13	307 2.4×	56 0.4×	182 1.5×	120 1.1×	54 0.6×	82	578
D Samson United Kingdom	12	372 2.9×	42 0.3×	159 1.3×	115 1.0×	81 0.9×	23	560
In Sang Jeon South Korea	13	65 0.5×	104 0.8×	22 0.2×	172 1.6×	180 2.1×	53	794
Dilip L. Solanki United States	14	183 1.4×	74 0.6×	175 1.4×	55 0.5×	42 0.5×	23	468
Kathleen Shields United States	11	85 0.7×	75 0.6×	66 0.5×	91 0.8×	148 1.7×	33	634
Xingming Chen China	15	18 0.1×	108 0.9×	14 0.1×	169 1.5×	174 2.0×	68	653
Yishan Ye China	12	126 1.0×	22 0.2×	27 0.2×	100 0.9×	89 1.0×	56	506
Joseph Maakaron United States	12	126 1.0×	30 0.2×	73 0.6×	251 2.3×	79 0.9×	65	465
Eiko Hayase Japan	13	169 1.3×	33 0.3×	22 0.2×	162 1.5×	177 2.1×	31	502

Countries citing papers authored by Ryuta Asada

Since Specialization

Citations

This map shows the geographic impact of Ryuta Asada's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ryuta Asada with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ryuta Asada more than expected).

Fields of papers citing papers by Ryuta Asada

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ryuta Asada. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ryuta Asada. The network helps show where Ryuta Asada may publish in the future.

Co-authorship network of co-authors of Ryuta Asada

This figure shows the co-authorship network connecting the top 25 collaborators of Ryuta Asada. A scholar is included among the top collaborators of Ryuta Asada based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ryuta Asada. Ryuta Asada is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Asada, Ryuta, Takuma Ishihara, Yoji Ueda, et al.. (2025). Evaluating the Efficacy and Safety of 48-Week Low-Dose Dienogest Administration in Patients With Dysmenorrhea Caused by Endometriosis: Protocol for a Randomized, Open-Label, Parallel-Group Trial. JMIR Research Protocols. 14. e66246–e66246.

Mori‐Yoshimura, Madoka, Naoki Suzuki, Masahisa Katsuno, et al.. (2023). Efficacy confirmation study of aceneuramic acid administration for GNE myopathy in Japan. Orphanet Journal of Rare Diseases. 18(1). 241–241. 8 indexed citations

Suzuki, Naoki, Madoka Mori‐Yoshimura, Masahisa Katsuno, et al.. (2023). Phase II/III Study of Aceneuramic Acid Administration for GNE Myopathy in Japan. Journal of Neuromuscular Diseases. 10(4). 555–566. 10 indexed citations

Shimizu, Shinya, Tatsunori Hanai, Yusuke Egashira, et al.. (2023). Controlling nutritional status score during hospitalization as a predictor of clinical outcome in patients with aneurysmal subarachnoid hemorrhage. Scientific Reports. 13(1). 12758–12758. 1 indexed citations

Sumi, Eriko, Taito Miyamoto, Ryuji Uozumi, et al.. (2022). Safety of the cyclin dependent kinase 9 (CDK9) inhibitor FIT039 for cervical intraepithelial neoplasia (CIN) 1 or 2 in a phase I/II trial.. Journal of Clinical Oncology. 40(16_suppl). 3022–3022. 1 indexed citations

Koga, Yuhki, Masahiro Sekimizu, Akihiro Iguchi, et al.. (2020). Phase I study of brentuximab vedotin (SGN-35) in Japanese children with relapsed or refractory CD30-positive Hodgkin’s lymphoma or systemic anaplastic large cell lymphoma. International Journal of Hematology. 111(5). 711–718. 5 indexed citations

Iseki, Masahiro, Masamichi Mizuma, Shohei Wakao, et al.. (2020). The evaluation of the safety and efficacy of intravenously administered allogeneic multilineage-differentiating stress-enduring cells in a swine hepatectomy model. Surgery Today. 51(4). 634–650. 14 indexed citations

Fukano, Reiji, Tetsuya Mori, Masahiro Sekimizu, et al.. (2020). Alectinib for relapsed or refractory anaplastic lymphoma kinase‐positive anaplastic large cell lymphoma: An open‐label phase II trial. Cancer Science. 111(12). 4540–4547. 64 indexed citations

Sumi, Eriko, Ryuta Asada, Ying Lü, Toshiko Ito‐Ihara, & Kevin Grimes. (2020). A Qualitative Study on the Differences Between Trial Populations and the Approved Therapeutic Indications of Antineoplastic Agents by 3 Regulatory Agencies From 2010 to 2018. Clinical Therapeutics. 42(2). 305–320.e0. 3 indexed citations

10.

Asada, Ryuta, et al.. (2019). A descriptive research: Exclusion from submitted clinical data package in the review process of new drug approval due to GCP violation in Japan. Contemporary Clinical Trials Communications. 15. 100416–100416. 2 indexed citations

11.

Ozeki, Michio, et al.. (2019). The impact of sirolimus therapy on lesion size, clinical symptoms, and quality of life of patients with lymphatic anomalies. Orphanet Journal of Rare Diseases. 14(1). 141–141. 67 indexed citations

12.

Sekimizu, Masahiro, Reiji Fukano, Ilseung Choi, et al.. (2018). Phase II Trial of CH5424802 (alectinib hydrochloride) for Recurrent or Refractory ALK-Positive Anaplastic Large Cell Lymphoma. Blood. 132(Supplement 1). 2924–2924. 2 indexed citations

13.

Suzuki, Naoki, Masaaki Kato, Hitoshi Warita, et al.. (2018). Phase I clinical trial results of aceneuramic acid for GNE myopathy in Japan. SHILAP Revista de lepidopterología. 3(1). 5 indexed citations

14.

Warita, Hitoshi, Masaaki Kato, Ryuta Asada, et al.. (2018). Safety, Tolerability, and Pharmacodynamics of Intrathecal Injection of Recombinant Human HGF (KP‐100) in Subjects With Amyotrophic Lateral Sclerosis: A Phase I Trial. The Journal of Clinical Pharmacology. 59(5). 677–687. 19 indexed citations

15.

Nagai, Hirokazu, Reiji Fukano, Masahiro Sekimizu, et al.. (2017). Phase II trial of CH5424802 (alectinib hydrochloride) for recurrent or refractory ALK-positive anaplastic large cell lymphoma: study protocol for a non-randomized non-controlled trial.. PubMed. 79(3). 407–413. 6 indexed citations

16.

Yamamoto, Naoki, Ryuta Asada, Ryuji Kawahara, et al.. (2017). Prevalence of, and risk factors for, carriage of carbapenem-resistant Enterobacteriaceae among hospitalized patients in Japan. Journal of Hospital Infection. 97(3). 212–217. 77 indexed citations

17.

Kuroda, Yutaka, Ryuta Asada, Kazutaka So, et al.. (2015). A pilot study of regenerative therapy using controlled release of recombinant human fibroblast growth factor for patients with pre-collapse osteonecrosis of the femoral head. International Orthopaedics. 40(8). 1747–1754. 43 indexed citations

18.

Asada, Ryuta, Shinobu Shimizu, Shunsuke Ono, et al.. (2013). Analysis of new drugs whose clinical development and regulatory approval were hampered during their introduction in Japan. Journal of Clinical Pharmacy and Therapeutics. 38(4). 309–313. 3 indexed citations

19.

Wang, Jean, Takashi Kimura, Ryuta Asada, et al.. (2003). SCID-repopulating cell activity of human cord blood-derived CD34- cells assured by intra-bone marrow injection. Blood. 101(8). 2924–2931. 166 indexed citations

20.

Ichida, Fukiko, Tetsuya Konishi, Ryuta Asada, et al.. (1985). Chlorambucil central nervous toxicity: a significant side effect of chlorambucil therapy in childhood nephrotic syndrome. European Journal of Pediatrics. 144(3). 283–286. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact